Our results demonstrating marked reduction in SARS-CoV-2 replication in AEC cultures treated with recombinant IFNβ1 or IFNλ2 provides further mechanistic evidence to support the possible use of inhaled interferon as a possible treatment option if initiated early enough during COVID-19. Here, IFNB1 is linked to COVID-19.